Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Eliquis generic date?

See the DrugPatentWatch profile for Eliquis

Do you mean the United States or another country?

In the U.S., there is currently no generic Eliquis (apixaban) on the market. Generic versions would only be allowed after all relevant patents expire and any related litigation and regulatory steps are resolved. The timing is uncertain and depends on patent outcomes, but many projections point to a generic launch in the 2026–2027 timeframe. However, exact dates can shift with court decisions and exclusivities.

If you tell me your country, I can give a more specific answer and point you to the official sources (FDA/Orange Book or equivalent) for the latest status.



Other Questions About Eliquis :

Wann lauft patent eliquis aus? Eliquis wann fallt das patent? What is the wac cost of eliquis 2 5mg? Eliquis vs pradaxa cost? When's the patent on eliquis to expire? Eliquis global sales 2024? Is eliquis under patent or not?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Low

Summary

No AI-generated prescribing-information alignment response is provided to evaluate. The supplied content appears to be label text and an internal evaluation artifact, not an AI response containing specific claims about Eliquis that can be checked against the provided label excerpts.


Category Scores

Indication
0
Poor
Indication
0
Poor

Accurate Statements


Unsupported Statements

The provided content includes an evaluation structure with fields such as determination/supported/contradicted, but it is not an FDA label-aligned AI response to a warning text; therefore, no verifiable label-to-response claim alignment can be assessed.
No actual AI response text with substantive claims is present to compare against the supplied prescribing information excerpts.

Contradictions


Important Omissions

A concrete AI-generated warning/label alignment response containing explicit statements about Eliquis (e.g., phrasing of recommendations, risks, timing, or monitoring) to evaluate against the provided FDA label sections.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
Because no evaluable AI-generated clinical/safety statements were provided, there is no basis to assess potential patient harm from inaccuracies.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

No Response Provided

Primary Issue
Cannot evaluate alignment because no AI-generated response text with Eliquis claims was provided.

Suggested Improvement
Provide the specific AI-generated response to be audited (the warning text/claims) so it can be checked statement-by-statement against the supplied FDA label excerpts (e.g., Sections 5.1 and 5.3, and any dosing/timing content if mentioned).

Drug Brand Mention Assessment

Branding Score
49
Visibility
58
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

“Eliquis generic date” usually refers to when generic apixaban can be marketed in the U.S.


Core Claims
  • “Eliquis generic date” usually refers to when generic apixaban can be marketed in the U.S.
  • The timeline depends on patent and exclusivity timelines.
  • Public reporting around Eliquis’ patent landscape is used to estimate when FDA/market entry could occur.
  • DrugPatentWatch tracks key patent/exclusivity events tied to Eliquis (apixaban).
  • Check the Eliquis page for the specific “generic”/“patent” date(s) it lists for the U.S.
Differentiators
  • Eliquis generic dates depend on patent and exclusivity timelines.
  • Estimates are anchored to specific patents/exclusivity tracked.
  • Generic timeline varies based on which endpoints are reported (patent expiration vs. market exclusivity vs. ANDA approval/launch).

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 61%
50 #2 No